US EditionJohnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
- Johnson & Johnson announced that its TAR-200 treatment achieved an over 80 percent disease-free survival rate in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease.
- Ninety-Four percent of patients treated with TAR-200 were able to preserve their bladder, and 95 percent had no progression of the disease at nine months, according to the study results.
- Initial results revealed strong disease-free survival rates of 85.3 percent at six months and 81.1 percent at nine months, highlighting TAR-200's effectiveness.
- Experts noted that TAR-200 can improve patient outcomes while preserving quality of life, as it may prevent the drastic impact of bladder removal surgery.
Insights by Ground AI
Does this summary seem wrong?
26 Articles
26 Articles
All
Left
3
Center
6
Right
4
The Courier-Tribune+23 Reposted by 23 other sources
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
Coverage Details
Total News Sources26
Leaning Left3Leaning Right4Center6Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 23%
C 46%
R 31%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
